{
  "url": "https://struct.news/briefs/kymeras-revenue-jumped-nearly-sixfold-its-cash-balance-fell-63",
  "title": "Kymera’s revenue jumped nearly sixfold. Its cash balance fell 63%.",
  "summary": "The biotech generated $65.0 million of revenue in three months, but held just $124.5 million in cash at June 30.",
  "published_at": "2026-08-05T11:19:31.686647+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Kymera Therapeutics, Inc.",
    "ticker": "KYMR",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-05",
    "accession": "0001193125-26-333849",
    "url": "https://www.sec.gov/Archives/edgar/data/1815442/000119312526333849/kymr-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-11",
    "url": "https://www.sec.gov/Archives/edgar/data/1815442/000095017025106229/kymr-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 39211000,
      "display": "$39.2M",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-333849",
        "filing_date": "2026-08-05"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": -16.699949014276005,
      "display": "-16.7%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-333849",
        "filing_date": "2026-08-05"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -891.0739333350335,
      "display": "-891.1%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-333849",
        "filing_date": "2026-08-05"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "R&D rose to $119.5 million, including a $36.1 million increase tied to the STAT6 program and higher internal investment.",
      "importance": "medium",
      "evidence": "The increase of $59.0 million was primarily due to a $36.1 million increase in costs related to our STAT6 program",
      "source_date": "2026-08-05"
    }
  ],
  "related_tickers": [
    "KYMR"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}